HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

STAT+: More political interference at the FDA?

A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.

By STAT News · May 7, 2026 · via STAT News
STAT+: More political interference at the FDA?

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News →

Tags
policyformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
Touting $529B in savings over 10 years, White House looks to expand MFN deals with pharma
PolicyFiercePharma ↗
Touting $529B in savings over 10 years, White House looks to expand MFN deals with pharma
Following a series of “most favored nation” pricing deals with 17 large pharma companies, the Trump administra…
May 7, 2026
Status of State Medicaid Expansion Decisions
PolicyKFF Health News ↗
Status of State Medicaid Expansion Decisions
This page displays an interactive map of the current status of state decisions on the Affordable Care Act's Me…
May 6, 2026
Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court
PolicyKFF Health News ↗
Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court
This brief reviews the case now before the Supreme Court, Louisiana v. FDA, and provides an overview of the ot…
May 6, 2026